Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometry

US10037874B2 · kind B2 · utility

Assignees

• Biodesix, Inc. · US
• The Board of Regents of the University of Texas System · US

Inventors

• Joanna Röder · Steamboat Springs, US
• Carlos Oliveira · Aurora, US
• Julia Grigorieva · Steamboat Springs, US
• Heinrich Röder · Steamboat Springs, US
• Devalingam Mahalingam · San Antonio, US

Key dates

• Filing date: Nov 10, 2015
• Grant date: Jul 31, 2018
• Expiry date: Aug 16, 2036

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A90/10
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

Hepatocellular carcinoma (HCC) is detected in a patient with liver disease. Mass spectrometry data from a blood-based sample from the patient is compared to a reference set of mass-spectrometry data from a multitude of other patients with liver disease, including patients with and without HCC, in a general purpose computer configured as a classifier. The classifier generates a class label, such as HCC or No HCC, for the test sample. A laboratory system for early detection of HCC in patients with liver disease is also disclosed. Alternative testing strategies using AFP measurement and a reference set for classification in the form of class-labeled mass spectral data from blood-based samples of lung cancer patients are also described, including multi-stage testing.